LBT Innovations receives APAS instrument orders
Laboratory device manufacturer LBT Innovations has received an order for multiple APAS instruments from its US distributor Remel Inc, a division of Thermo Fisher Scientific. The company has been commercialising its APAS Independence laboratory instrument, an imaging, interpretation, sorting and reporting machine that automatically examines culture plates for the presence of bacterial colonies. LBT said the order was expected to accelerate early sales opportunities in the US and would support the placement of instruments in key sector opinion leaders. This is the first order LBT has received from Remel.
First Graphene in South African distribution deal
Graphene manufacturer First Graphene has inked a distribution deal to supply South Africa’s Nanoproof Glade Chemical Manufacturers JV with graphene for the construction market. The company will supply its PureGRAPH graphene for multiple used including as an admixture for concrete, grouts and mortars. Nanoproof will purchase a minimum of five tonnes of PureGRAPH Aqua over a four year period, valued at up to $285,000 a year. The addition of graphene reduces CO2 emissions by 25 per cent by reducing the amount of cement used in a concrete mix.
Anagenics progresses restructure
Health and beauty business Anagenics is progressing the restructure of its businesses following the purchase of BLC Cosmetics and the merging of the two businesses. The leadership team has undertaken a strategic review prioritising the building of revenue and reduction of operating costs to improve profitability and cashflow. CEO Matthew Dudek announced immediate forecast annualised savings of more than $1 million. One change is the merging of Anagenics’ Advangen 3PL operations into 3PL’s warehouse. Anagenics sells anti-ageing and cosmeceutical and wellness brands.
Imagion Biosystems progresses in-human trials
Cancer detection company Imagion Biosystems has progressed trials of its non-radioactive MagSense HER2 breast cancer test for HER2 positive breast cancer. The test, which detects if tumours have metastasized to the lymph nodes, replaces today’s practice requiring surgical biopsies of the lymph notes. Specialised MagSense nanoparticles are coated with tumour targeting antibodies and located by weak magnetic fields. Trials on the first five patients have revealed no safety issues related to the MagSense imaging agent with all tolerating the injected dosages. Imagion is encouraged by the early results and plans to continue the study.
Picture: Imagion Biosystems
Subscribe to our free @AuManufacturing newsletter here.